Consensus for HER2 alterations testing in non-small-cell lung cancer
Shengxiang Ren(Tongji University), Fred R. Hirsch(University of Colorado Denver), Daniel Lee(Ulsan College), Philip C. Mack(UC Davis Comprehensive Cancer Center), Bo Zhu(Army Medical University), X. Wang(Qilu Hospital of Shandong University), Zengwu Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), C. Wang(Tianjin Medical University Cancer Institute and Hospital), Jianchun Duan(Chinese Academy of Medical Sciences & Peking Union Medical College), Baohui Han(Shanghai Jiao Tong University), Yu Yao(First Affiliated Hospital of Xi'an Jiaotong University), Caicun Zhou(Tongji University), Yongqian Shu(Nanjing Medical University), L. Zhang(Sun Yat-sen University), Ying Cheng(Jilin Province Tumor Hospital), Yi Xu(Tongji University), Zhaoguang Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Tetsuya Mitsudomi(Kindai University), Jiong Wang(Wenzhou Medical University), Jing Liu(First Affiliated Hospital of Dalian Medical University), Mingfang Zhao(First Hospital of China Medical University), Jun Zhang(Wuhan University), You Lü(Jiangsu Cancer Hospital), Yong Song(Nanjing General Hospital of Nanjing Military Command), Qibin Song(Wuhan University), Meiqi Shi(Jiangsu Cancer Hospital), Xia Song(Shanxi Provincial Cancer Hospital), A. Liu(Nanchang University), Yun Fan(Chinese Academy of Sciences), Jianming Ying(Chinese Academy of Medical Sciences & Peking Union Medical College), Z. Ma(Zhengzhou University), Zhouguang Hui(Chinese Academy of Medical Sciences & Peking Union Medical College)
Cited by 110
Related Papers
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
|Journal of Thoracic Oncology|2011|4.8k
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
|Science|2007|4.5k
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Lung cancer: current therapies and new targeted treatments
|The Lancet|2016|3.3k